AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy has been approved in the U.S. for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. The approved regimen includes neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by adjuvant Imfinzi in combination with chemotherapy, then Imfinzi monotherapy.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Novo Nordisk’s Ozempic and Wegovy Prices Cut 71% under Medicare Plan
- FDA approves AstraZeneca’s Imfinzi as perioperative immunotherapy for GEJ cancer
- AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation
- Harbour BioMed advances collaboration with AstraZeneca
- AstraZeneca plans $2B manufacturing investment in Maryland